Read by QxMD icon Read


(no author information available yet)
▼Canagliflozin and risk of lower limb amputation ● Antidepressants and young people ● Biological interventions for fatigue in RA ● Body shape in early and midlife linked to mortality ● COPD: LABA plus LAMA versus LABA plus ICS ● Safety warning for Nexplanon (etonogesterel) contraceptive implants ● Incorporating long-term prognosis into the care of older adults ● Impact of moderate-to-vigorous physical activity on cancer risk.
August 2016: Drug and Therapeutics Bulletin
C Simon, M S Agier, J Béné, C Muller, L Vrignaud, H Marret, A P Jonville-Bera
OBJECTIVES: The aim of the study was to assess the incidence of adverse effects (AE) reported with etonogestrel contraceptive implant in France (Implanon(®) and Nexplanon(®)). MATERIALS AND METHODS: All cases of AE or unintended pregnancies reported to health authorities or to the firm were analyzed. RESULTS: During 10 years, 5433 AE and 789 unintended pregnancies were reported. Only 388 (7 %) were serious. There were 1137 reports of difficulties to remove, failure to locate or migration, 430 of insertion difficulties and 203 of deformation or expulsion of the implant...
April 25, 2016: Journal de Gynécologie, Obstétrique et Biologie de la Reproduction
Alison M Stuebe, Amy G Bryant, Robyn Lewis, Anitha Muddana
BACKGROUND: Studies have not found that hormonal contraceptive implants adversely affect breastfeeding, but theoretical concerns exist. METHODS: We reported a case of reduced weight gain in an exclusively breastfed infant in association with placement of (ENG)-releasing contraceptive implant (Nexplanon) to the FDA Adverse Events Reporting System (FAERS). We further queried reports to FAERS and reviewed published studies of the ENG implant during breastfeeding. RESULTS: A breastfeeding mother received an ENG implant at 4 weeks postpartum...
May 2016: Breastfeeding Medicine: the Official Journal of the Academy of Breastfeeding Medicine
Kim C Dobromilsky, Penny L Allen, Stephen H Raymond, Bhavna Maindiratta
BACKGROUND: Etonogestrel (ENG) implants (Implanon(®)/Nexplanon(®)/Implanon NXT(®)) are employed as contraception in early postpartum patients. Follow-up is often not conducted by the hospital prescriber. Little is known about duration of lochia, in a modern setting, and even less is known about the effect of ENG implants on lochia. AIMS: To determine if early postpartum (pre-discharge) insertion of Implanon for contraception was associated with a significant difference in duration of lochia...
July 2016: Journal of Family Planning and Reproductive Health Care
A Lafuma, A Agostini, T Linet, J Robert, L Levy-Bachelot, C Godard
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Lucy Michie, Sharon T Cameron, Anna Glasier, Anne Johnstone
BACKGROUND: To provide standardised information about the contraceptive implant (Nexplanon(®)), a digital video disc (DVD) was developed for use within a sexual and reproductive health (SRH) service in Edinburgh. The aim was to determine if the accuracy of information recalled after watching a DVD was comparable to that following a face-to-face consultation, and if patients found the use of a DVD acceptable. METHODS: Fifty women attending an SRH service abortion clinic considering using Nexplanon for the first time agreed to be randomised to receive information about the implant either by (a) a DVD (n=35) developed using information taken from Faculty of Sexual & Reproductive Healthcare guidance or (b) a face-to-face consultation (n=15)...
July 2016: Journal of Family Planning and Reproductive Health Care
Costantino Di Carlo, Maurizio Guida, Nicoletta De Rosa, Anna Sansone, Virginia Gargano, Angelo Cagnacci, Carmine Nappi
PURPOSE: The purpose of this study is to evaluate the menstrual profile in users of the etonogestrel (ENG)-releasing implant (Nexplanon®) and the possible correlation with anthropometric variables. METHODS: Ninety-two healthy women, desiring long-term contraception with the ENG implant were enrolled in a prospective observational study. Anthropometric variables were measured at baseline and after 3, 6, 9, and 12 months. Patients recorded daily the occurrence of any bleeding or spotting...
June 2015: Gynecological Endocrinology
Célia Pedroso, Isabel Martins, Fátima Palma, Ana Isabel Machado
Nexplanon (Schering-Plough Limited/Merck Sharp & Dohme Limited (MSD)) is a long active reversible contraceptive method that provides effective contraception for 3 years. It consists of a single, flexible, rod-shaped implant, containing 68 mg etonogestrel. It is 4 cm long, consists of an ethylene vinyl acetate copolymer, a non-absorbable material, and also contains 15 mg of barium sulfate, which makes it visible by X-ray. We describe a case of a 39-year-old woman who experienced a local reaction to the barium sulfate in Nexplanon...
2015: BMJ Case Reports
Deepak Khatri
No abstract text is available yet for this article.
January 2015: Journal of Family Planning and Reproductive Health Care
Anne Connolly, Guilhem Pietri, Jingbo Yu, Samantha Humphreys
BACKGROUND: Since the late 1990s, the British government has launched major strategies to address high teenage pregnancy and abortion rates in England. These have focused in part on improving access to contraception through national campaigns. This study assessed teenage pregnancy and abortion rate trends since 1998 and possible associations with usage of long-acting reversible contraceptives (LARCs). METHODS: Teenage conception rates and age-specific abortion rates were obtained from the Office for National Statistics and the Department of Health...
2014: International Journal of Women's Health
Maurizio Serati, Giorgio Bogani, Sanjeev Kumar, Antonella Cromi, Fabio Ghezzi
Nexplanon® is an etonogestrel implant with a long-acting contraceptive effect. Although several studies underlined its safety profile, its implant can rarely lead to moderate or severe adverse event. Here, we presented a case of delayed-type hypersensitivity reaction against Nexplanon® that resolved after its removal.
January 2015: Contraception
Maryam Guiahi, Kristina Tocce, Stephanie Teal, Tyler Green, Paul Rochon
Despite modifications to avoid deep insertions, clinical experience with Nexplanon demonstrates that deep insertions still occur. We present a case of a Nexplanon found in the biceps muscle that was successfully removed with a small incision using a combination of ultrasound and fluoroscopy guidance by interventional radiologists.
December 2014: Contraception
Farah Chaudhry
No abstract text is available yet for this article.
January 2014: Journal of Family Planning and Reproductive Health Care
Costantino Di Carlo, Anna Sansone, Nicoletta De Rosa, Virginia Gargano, Giovanni Antonio Tommaselli, Carmine Nappi, Giuseppe Bifulco
The aim of the study was to determine the impact of etonogestrel (ENG)-implant used for contraceptive purpose on Quality of life (QoL) and on sexual function (FSF) of healthy Italian women. The Female Sexual Function Index (FSFI) questionnaire and the Short Form-36 (SF-36) validated questionnaire were administered at baseline, 3 and 6 months after insertion of Nexplanon. The implant seems to have a positive impact on QoL after the first three months of therapy. Users showed an improved general health status and physical role status...
January 2014: Gynecological Endocrinology
Mary Pillai, A Caroline Gazet, Megan Griffiths
BACKGROUND AND METHODOLOGY: Information is presented on the management of women referred to a sexual health service during a 1-year period for management of a non-palpable contraceptive implant or of a palpable implant considered unsuitable for routine removal. RESULTS: Fifty-two women were referred. Thirty-four implants were non-palpable and their depth on ultrasound ranged from 2.7 to 12mm. Seventeen were fully or partly palpable and their depth ranged from 3mm or less (16 cases) to 5...
April 2014: Journal of Family Planning and Reproductive Health Care
Vaishali Purbey
No abstract text is available yet for this article.
October 2013: Journal of Family Planning and Reproductive Health Care
Rachael Partridge, Jane Bush
No abstract text is available yet for this article.
October 2013: Journal of Family Planning and Reproductive Health Care
Farah Chaudhry
No abstract text is available yet for this article.
October 2013: Journal of Family Planning and Reproductive Health Care
Ken Menon
No abstract text is available yet for this article.
October 2013: Journal of Family Planning and Reproductive Health Care
Ellen Mommers, Georges-Fabrice Blum, Thomas G Gent, Klaus P Peters, Terje S Sørdal, Maya Marintcheva-Petrova
OBJECTIVE: To investigate the efficacy, safety, removal characteristics, and x-ray visibility of Nexplanon, a radiopaque etonogestrel contraceptive implant combined with a next-generation applicator. STUDY DESIGN: A 3-year, nocomparative, multicenter study in women aged 18-40 years at 23 clinical sites. RESULTS: Of 301 women who had an implant inserted, none became pregnant while the implant was in situ. Serious adverse events were reported in 16 of 301 (5...
November 2012: American Journal of Obstetrics and Gynecology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"